Amgen/Wyeth Enbrel
Executive Summary
Wyeth/Amgen's Enbrel clears FDA Aug. 21 for supplemental indication of "inhibiting the progression of structural damage of active arthritis in patients with psoriatic arthritis." Enbrel (etanercept) was approved for "reducing the signs and symptoms" of psoriatic arthritis in 2002 (1"The Pink Sheet" Jan. 21, 2002, p. 25)...
You may also be interested in...
Immunex Enbrel Psoriatic Arthritis 12-Month Data To Follow sBLA Approval
Immunex plans to submit 12-month, open-label Enbrel data in psoriatic arthritis patients following FDA's Jan. 16 approval of etanercept for the supplemental indication
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.